Cervarix
Cervarix is a vaccine against certain types of cancer-causing human papillomavirus (HPV).
| Vaccine description | |
|---|---|
| Target | human papillomavirus (Types 16 and 18) |
| Vaccine type | Protein subunit |
| Clinical data | |
| Trade names | Cervarix |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a610014 |
| Routes of administration | Intramuscular injection |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| (what is this?) (verify) | |
Cervarix is designed to prevent infection from HPV types 16 and 18, that cause about 70% of cervical cancer cases. These types also cause most HPV-induced genital and head and neck cancers. Additionally, some cross-reactive protection against virus strains 45 and 31 were shown in clinical trials. Cervarix also contains AS04, a proprietary adjuvant that has been found to boost the immune system response for a longer period of time.
Cervarix is manufactured by GlaxoSmithKline. An alternative product, from Merck & Co., is known as Gardasil. Cervarix was voluntarily taken off of the market in the US in 2016 due to low demand.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.